Generic placeholder image

Current Diabetes Reviews


ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Adapting the GLP-1-Signaling System to the Treatment of Type 2 Diabetes

Author(s): Teresa Salvatore, Ornella Carbonara, Domenico Cozzolino, Roberto Torella and Ferdinando Carlo Sasso

Volume 3, Issue 1, 2007

Page: [15 - 23] Pages: 9

DOI: 10.2174/157339907779802076

Price: $65


Glucagon-like peptide-1 (GLP-1) may contribute to the decreased incretin effect characterizing type 2 diabetes. Multiple actions other than insulin secretion stimulation give to GLP-1 a highly desirable profile for an antidiabetic agent. To overcome the need for continuous infusion of the native compound, which is rapidly degraded by dimetyl peptidil peptidase-IV (DPP-IV), analogues with low affinity for this protease have been developed. A second major strategy is represented by DPP-IV inhibitors that act to increase endogenous GLP-1. On the basis of the promising results in clinical trials, the incretin-based therapy may offer an useful option for diabetes management.

Keywords: Incretin effect, Glucagon-like peptide-1, Type 2 diabetes, GLP-1R agonists, DPP-IV inhibitors

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy